CRMD CorMedix Inc.
Legal ·
The class action names CorMedix and six officers, including Khoso Baluch. A settlement of derivative suits naming 12 individuals had a final approval hearing set for September 23, 2026.
CorMedix wants stockholders to ratify earlier changes to its Series E and Series C-3 preferred stock, and to let preferred holders alone approve future changes to those terms.
CorMedix paid $260 million in cash and $40 million in common shares to Melinta's owners. A contingent payment agreement adds up to $25 million tied to a rezafungin approval by June 30, 2029.
CorMedix closed a $150,000,000 private placement of 4.00% convertible senior notes due 2030 on August 12, 2025. Each $1,000 of principal converts into 74.2515 common shares at the initial rate, and U.S. Bank Trust Company is trustee under the new indenture.
The 4.00% notes were sold in a private placement. The initial conversion rate is 74.2515 shares of common stock per $1,000 principal amount.
CorMedix said it will buy Melinta Therapeutics, with closing targeted as early as September 1, 2025. The company's August 7 release gives no price, no financing and no adviser for the deal.
CorMedix is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. Its main commercial product is DefenCath (taurolidine and heparin), an antimicrobial catheter lock solution that the FDA approved to reduce catheter-related bloodstream infections in adults with kidney failure receiving chronic hemodialysis through a central venous catheter. The company launched DefenCath in April 2024 in the inpatient setting and in July 2024 in the outpatient hemodialysis setting, and says it is its largest contributor to net sales. On August 29, 2025 it acquired Melinta Therapeutics, adding six marketed, hospital- and clinic-focused infectious disease products: REZZAYO, MINOCIN IV, VABOMERE, KIMYRSA, ORBACTIV and BAXDELA. The acquisition also added TOPROL-XL. The company plans to pursue expanded indications for DefenCath to reduce central line associated bloodstream infection in adults receiving total parental nutrition, and for REZZAYO in prophylaxis of invasive fungal infections in immunocompromised adults.
| Product or program | What it is | Stage |
|---|---|---|
| DefenCath | Antimicrobial catheter lock solution for hemodialysis patients | approved |
| REZZAYO | Rezafungin for injection, a hospital infectious disease product | marketed |
| MINOCIN IV | Minocycline for injection, a hospital infectious disease product | marketed |
| VABOMERE | Meropenem and vaborbactam, a hospital infectious disease product | marketed |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $311.7 million | $43.5 million |
| Research and development | $19.3 million | $3.9 million |
| Net income (loss) | $163.1 million | -$17.9 million |
| Cash from operations | $175.0 million | -$50.6 million |
| Cash and equivalents | $144.8 million | $40.7 million |
| Short-term investments | $3.7 million | $11.0 million |
Our latest story on this, dated Aug 13, 2026: "CorMedix faces DefenCath securities class action as derivative settlement heads to a hearing". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Aug 12, 2025: "CorMedix completes $150,000,000 convertible senior notes private placement due 2030". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Aug 12, 2025: "CorMedix completes $150,000,000 convertible senior notes private placement due 2030". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Aug 13, 2026: "CorMedix faces DefenCath securities class action as derivative settlement heads to a hearing". The story links the filing or release it is based on. Read the story.
CorMedix Inc. trades under the ticker CRMD on NASDAQ.
CorMedix Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:19KA; LSX:A2PF3G.
The SEC Central Index Key (CIK) for CorMedix Inc. is 1410098. Its filings are on SEC EDGAR.
77,944,324 shares as of 2026-08-10, per the cover page of its 10-Q filed 2026-08-13.
Our directory records CorMedix Inc. under United States.
Our directory classifies CorMedix Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for CorMedix Inc. is US21900C3088.
aibio.space lists CorMedix Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
CorMedix is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. Its main commercial product is DefenCath (taurolidine and heparin), an antimicrobial catheter lock solution that the FDA approved to reduce catheter-related bloodstream infections in adults with kidney failure receiving chronic hemodialysis through a central venous catheter.
DefenCath: Antimicrobial catheter lock solution for hemodialysis patients Stage: approved.
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 8-K (Items 8.01,9.01). Source
Reported a change of independent auditor. SEC Form 8-K (Items 4.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,2.02,3.02,7.01,8.01,9.01). Source
Reported a financing. SEC Form 424B5. Source
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio